Zhe-Sheng (Jason) Chen
Basic info is private.
3
Articles
31
Download
Interests
Cancer pharmacology; Drug discovery; Multidrug resistance (MDR)
Latest Publications
Open Access Original Research
ABCB1 limits the cytotoxic activity of TAK-243, an inhibitor of the ubiquitin-activating enzyme UBA1
Zhuoxun Wu, Yuqi Yang, Zining Lei, Silpa Narayanan, ... Zhesheng Chen
Front. Biosci. (Landmark Ed) 2022, 27(1), 005; https://doi.org/10.31083/j.fbl2701005
25
Download
2
Citations
123
Views
Open Access Original Research
Poly (ADP-ribose) polymerase (PARP) inhibitors as chemosensitizing compounds for the treatment of drug resistant cancers
Narayanan Silpa, Teng Qiu-Xu, Koya Jagadish, Wang Jingquan, ... Chen Zhe-Sheng
J. Mol. Clin. Med. 2019, 2(3), 55–67; https://doi.org/10.31083/j.jmcm.2019.03.0303
20
Download
1
Citations
56
Views
Open Access Original Research
KIT and PDGFRA inhibitor avapritinib (BLU-285) overcomes ABCB1- and ABCBG2-mediated MDR in cancer cells
Gupta Pranav, V. Ashar Yunali, Teng Qiu-Xu, Lei Zining, ... Chen Zhe-Sheng
J. Mol. Clin. Med. 2019, 2(3), 69–78; https://doi.org/10.31083/j.jmcm.2019.03.0301
6
Download
34
Views
Back to top